Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 11, 2024American Journal of HematologyOpen Access

Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real‐world data from eight US academic centers

View Full Paper
Ask AI
Bookmark
Share

Authors

YAYasmin AbazaNorthwestern UniversityEWEric S. WinerHarvard UniversityGMGuru Subramanian Guru MurthyMedical College of Wisconsin

Discussion

Loading...

Member takes

Implication

Multicenter retrospective study reveals real-world outcomes of hypomethylating agents plus venetoclax in elderly patients, highlighting urgent clinical needs.

Key Points

  • Complete remission was achieved in 38% of treated patients, indicating a high response rate.
  • Among 204 elderly patients, the median overall survival was 9.5 months, with worse outcomes for TP53 mutations.
  • This multicenter retrospective study assesses treatment patterns and tolerability of venetoclax combined with hypomethylating agents in acute myeloid leukemia patients aged 75 and older across eight centers in the US. The 30-day and 60-day mortality rates were notable at 9% and 19%, respectively.

Cite This Study

Abaza et al. (2024) studied this question.

synapsesocial.com/papers/68e7997bb6db64358770a0cchttps://doi.org/10.1002/ajh.27231
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia2003 · 2,686 citations
  2. 2Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia2020 · 2,955 citations
  3. 3Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations2022 · 171 citations
  4. 4Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax2021 · 64 citations
  5. 5Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens2020 · 182 citations